Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Sagar Vidya Siripurapu"'
Autor:
Tony S. K. Mok, Diego Luigi Cortinovis, Margarita Majem, Melissa Lynne Johnson, Feby Ingriani Mardjuadi, Xuan Zhao, Sagar Vidya Siripurapu, Zhiqiang Jiang, Juergen Wolf
Publikováno v:
Journal of Clinical Oncology. 40:9118-9118
9118 Background: Capmatinib is a selective MET inhibitor approved for patients (pts) with metastatic NSCLC harboring MET exon 14 skipping mutation. Pembrolizumab (pembro) is a programmed death protein-1 (PD-1) inhibitor approved as monotherapy for pt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6f9e741db56349bca1e8ebe334125933
https://doi.org/10.1200/jco.2022.40.16_suppl.9118
https://doi.org/10.1200/jco.2022.40.16_suppl.9118
